Pharvaris (PHVS) Expected to Announce Earnings on Tuesday

Pharvaris (NASDAQ:PHVS) is anticipated to announce its results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.8267) per share for the quarter.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Price Performance

Shares of NASDAQ:PHVS traded up $0.22 during mid-day trading on Tuesday, reaching $30.24. 96,907 shares of the company were exchanged, compared to its average volume of 197,820. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -8.97 and a beta of -2.34. The firm’s 50-day simple moving average is $27.62 and its 200 day simple moving average is $26.09. Pharvaris has a 1 year low of $14.59 and a 1 year high of $31.14.

Insiders Place Their Bets

In other Pharvaris news, insider Anne Lesage sold 19,200 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total transaction of $580,992.00. Following the sale, the insider directly owned 133,969 shares in the company, valued at $4,053,901.94. This represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the sale, the director owned 355,167 shares in the company, valued at $10,768,663.44. The trade was a 7.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 150,659 shares of company stock worth $4,489,587 in the last ninety days.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System raised its holdings in shares of Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Pharvaris by 5.7% in the 4th quarter. Swiss National Bank now owns 44,757 shares of the company’s stock valued at $1,242,000 after purchasing an additional 2,400 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PHVS shares. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wall Street Zen lowered shares of Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday, April 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wedbush increased their target price on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, Wolfe Research assumed coverage on shares of Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pharvaris has an average rating of “Moderate Buy” and a consensus target price of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.